UNSPSC 51162732: Oxymetazoline

This classification denotes an alpha-adrenergic agonist with the molecular formula C16H24N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 8VLN5B44ZY, chemically known as 6-tert-butyl-3-(2-imidazolin-2-ylmethyl)-2,4-dimethylphenol but more generally known as oxymetazoline, which bears US NIH Compound Identifier 4636. European Medicines Agency schedules Oxymetazoline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09567MIG.

UNSPSC 51162732 Oxymetazoline, a Commodity code, covers pharmaceutical products state and local governments procure for healthcare delivery to populations in custody and community settings. Recent solicitations show that state and local buyers source parenteral products—intravenous and parenteral nutrition solutions, controlled substances for medical use, and related equipment—and opioid-antagonist pharmaceuticals including naloxone through this code. The Washington State Department of Corrections and Seminole County, Florida have posted active solicitations, suggesting that correctional departments and county health agencies are primary buyers under this code. Suppliers must meet pharmaceutical licensing, controlled-substance handling, and insurance requirements (including Professional Liability and Cyber Liability coverage), and in the Washington DOC case, demonstrate documented experience preparing and delivering time-sensitive IV and parenteral nutrition solutions with overnight turnaround for customized formulations.

Activity appears concentrated in the Pacific Northwest and Southeast. The Washington State Department of Corrections issued RFQ RFQQK13020 on September 8, 2026, requesting parenteral products and services for eight correctional facilities across three regions (West, Central, and East Washington), with a due date of October 7, 2026 and a pre-bid conference on September 23, 2026; DOC anticipates awarding up to three bidders per region for an initial contract term running November 26, 2026 through June 30, 2030, with pricing fixed for the first two years. Seminole County, Florida posted IFB 60459723LAS requesting 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building; the bid closed July 26, 2023. The Washington procurement emphasizes set-aside participation targets for small, minority-owned, women-owned, and veteran-owned businesses under Washington's Chapter 39.19 RCW framework.